

PHASE 2 RESULTS INDICATE DURABILITY OF RESPONSE FOR ALLIGATOR'S CD40 AGONIST

BioStock interview with Alligator CMO, Sumeet Ambarkhane.

Following the **second round of interim results from OPTIMIZE-1**, the phase 2 trial with mitazalimab in pancreatic cancer patients, **BioStock** reached out to Alligator's CMO Sumeet Ambarkhane for an in-depth analysis.

[Click here to access today's interview.](#)

Attachments

[Phase 2 results indicate durability of response for Alligator's CD40 agonist](#)